The potential impact of increased treatment rates for alcohol dependence in the United Kingdom in 2004

BMC Health Services Research

Colin Drummond²  Gerrit Gmel³  Maximilien X Rehm¹  Jürgen Rehm⁵  Kevin D Shield⁴ 

[1] Faculty of Arts and Sciences/Politics and Governance, Ryerson University, Toronto, Toronto, Canada;National Addiction Centre, Institute of Psychiatry, King’s College London, London, UK;Centre for Addiction and Mental Health (CAMH), 33 Russell Street, Toronto, ON M5S 2S1, Canada;Institute of Medical Science, University of Toronto, Toronto, Canada;Department of Psychiatry, University of Toronto, Toronto, Canada

关键词: United Kingdom;    Alcohol dependence treatment;    Alcohol dependence;    Mortality;    Alcohol;   

Others  :  1134196
DOI  :  10.1186/1472-6963-14-53

 received in 2013-03-18, accepted in 2014-01-07,  发布年份 2014

【 摘 要 】

Background

Alcohol consumption has been linked to a considerable burden of disease in the United Kingdom (UK), with most of this burden due to heavy drinking and Alcohol Dependence (AD). However, AD is undertreated in the UK, with only 8% of those individuals with AD being treated in England and only 6% of those individuals with AD being treated in Scotland. Thus, the objective of this paper is to quantify the deaths that would have been avoided in the UK in 2004 if the treatment rate for AD had been increased.

Methods

Data on the prevalence of AD, alcohol consumption, and mortality were obtained from the Adult Psychiatric Morbidity Survey, the Global Information System on Alcohol and Health, and the 2004 Global Burden of Disease study respectively. Data on the effectiveness of pharmacological treatment and Motivational Interviewing/Cognitive Behavioural Therapy were obtained from Cochrane reviews and meta-analyses. Simulations were used to model the number of deaths under different treatment scenarios. Sensitivity analyses were performed to model the effects of Brief Interventions and to examine the effect of using AD prevalence data obtained from the National Institute for Health and Clinical Excellence.

Results

In the UK, 320 female and 1,385 male deaths would have been avoided if treatment coverage of pharmacological treatment had been increased to 20%. This decrease in the number of deaths represents 7.9% of all alcohol-attributable deaths (7.0% of all alcohol-attributable deaths for women and 8.1% of all alcohol-attributable deaths for men). If we used lower AD prevalence rates obtained from the National Institute for Health and Clinical Excellence, then treatment coverage of pharmacological treatment in hospitals for 20% of the population with AD would have resulted in the avoidance of 529 deaths in 2004 (99 deaths avoided for women and 430 deaths avoided for men).

Conclusions

Increasing AD treatment in the UK would have led to a large number of deaths being avoided in 2004. Increased AD treatment rates not only impact mortality but also impact upon the large burden of disability and morbidity attributable to AD, as well as the associated social and economic burdens.

【 授权许可】

   
2014 Shield et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, et al.: A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2224-2260.
• [2]Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J: Global burden of disease and injury and economic cost attributable to alcohol use and alcohol use disorders. Lancet 2009, 373(9682):2223-2233.
• [3]Rehm J, Shield KD, Rehm MX, Gmel G, Frick U: Modelling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol 2013, 23(2):89-97.
• [4]Ezzati M, Lopez A, Rodgers A, Murray CJL: Comparative quantification of health risks. Global and regional burden of disease attributable to selected major risk factors. Geneva, Switzerland: World Health Organization; 2004.
• [5]American Psychiatric Association: Diagnostic and statistical manual of mental disorders (4th edition, text revision). Washington, DC: American Psychiatric Association; 2000.
• [6]Dawson DA, Li TK, Grant BF: A prospective study of risk drinking: at risk for what? Drug Alcohol Depend 2008, 95:62-72.
• [7]Li TK, Hewitt BG, Grant BF: The alcohol dependence syndrome, 30 years later: a commentary. The 2006H. David Archibald lecture. Addiction 2007, 102(10):1522-1530.
• [8]Rehm J, Shield KD, Rehm MX, Gmel G Jr, Frick U: Alcohol Consumption, Alcohol Dependence, and Attributable Burden of Disease in Europe: Potential Gains from Effective Interventions for Alcohol Dependence. Toronto, Canada: Centre for Addiction and Mental Health; 2012.
• [9]European Commission: EU citizens’ Attitudes Towards Alcohol. Special Eurobarometer 331. Brussels, Belgium: TNS; 2010.
• [10]Bebbington P, Brugha T, Coid J, Crawford M, Deverill C, D’Souza J, Doyle M, Farrell M, Fuller E, Jenkins R, Jotangia D, Harris J, Hussey D, King M, McManus S, Meltzer H, Nicholson S, Palmer B, Pickup D, Purdon S, Sadler K, Scholes S, Smith J, Thompson J, Tyrer P, Wardle H, Weich S, Wessely S: Adult Psychiatric Morbidity in England, 2007. England, UK: The Health & Social Care Information Centre - Social Care Statistics; 2009.
• [11]Drummond C, Pilling S, Brown A, Copello A, Day E, Dervan J, Dyer M, Flanagan E, Fry J, Georgeson B, Gilvarry E, Glover N, Gosnall J, Harris L, Lewis JW, Lingford Hughes AR, Mavranezouli I, Mccarthy T, Morgan M, Noble S, Omarjee S, Phillips T, Roberts P, Satrettin R, Shields L, Sinclair J, Stockton S, Taylor C, Yesufu-Udechuku A: Alcohol use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence. London: National Institute for Health and Clinical Excellence; 2011.
• [12]Shield KD, Kehoe T, Gmel G, Rehm MX, Rehm J: Societal burden of alcohol. In Alcohol in the European Union Consumption, Harm and Policy Approaches. Edited by Anderson P, Møller L, Galea G. Copenhagen, Denmark: World Health Organization Regional Office for Europe; 2012:10-28.
• [13]Martin G, Rehm J: The effectiveness of psychosocial modalities in the treatment of alcohol problems in adults: a review of the evidence. Can J Psychiatry 2012, 57(6):350-358.
• [14]Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M: Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010., 9CD004332
• [15]Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M: Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010., 12CD001867
• [16]Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, ESEMeD/MHEDEA Investigators: Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004, 109(420):47-54.
• [17]Drummond DC, Oyefeso N, Phillips T, Cheeta S, DeLuca P, Perryman K, Winfield H, Jenner J, Cobain K, Galea S, Saunders V, Fuller T, Pappalardo D, Baker O, Christopolous A: Alcohol Needs Assessment Research Project: The 2004 National Alcohol Needs Assessment for England. London: Ministry of Health; 2005.
• [18]Drummond C, Deluca P, Oyefeso A, Rome A, Scrafton S, Rice P: Scottish Alcohol Needs Assessment. London: King’s College London; 2009.
• [19]World Health Organization: Global Status Report on Alcohol and Health. Geneva, Switzerland: World Health Organization; 2011.
• [20]Shield K, Rylett M, Gmel G, Gmel G, Kehoe-Chan T, Rehm J: Global alcohol exposure estimates by country, territory and region for 2005 – a contribution to the comparative risk assessment for the 2010 global burden of disease study. Addiction 2013, 108(5):912-922.
• [21]Rehm J, Rehn N, Room R, Monteiro M, Gmel G, Jernigan D, Frick U: The global distribution of average volume of alcohol consumption and patterns of drinking. Eur Addict Res 2003, 9(4):147-156.
• [22]Rehm J, Kehoe T, Gmel G, Stinson F, Grant B, Gmel G: Statistical modeling of volume of alcohol exposure for epidemiological studies of population health: the example of the US. Popul Health Metr 2010, 8:3. BioMed Central Full Text
• [23]Kehoe T, Gmel G Jr, Shield K, Gmel G Sr, Rehm J: Determining the best population-level alcohol consumption model and its impact on estimates of alcohol-attributable harms. Popul Health Metr 2012, 10(1):6. BioMed Central Full Text
• [24]Rothman KJ, Greenland S, Lash TL: Modern Epidemiology. 3rd edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
• [25]Smedslund G, Berg RC, Hammerstrom KT, Steiro A, Leiknes KA, Dahl HM, Karlsen K: Motivational interviewing for substance abuse. Cochrane Database Syst Rev 2011., 5CD008063
• [26]Magill M, Ray LA: Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs 2009, 70(4):516-527.
• [27]Project Match Research Group: Matching alcoholism treatment to client heterogeneity: project MATCH posttreatment drinking outcomes. J Stud Alcohol 1997, 58:7-30.
• [28]McQueen J, Howe TE, Allan L, Mains D, Hardy V: Brief interventions for heavy alcohol users admitted to general hospital wards. Cochrane Database Syst Rev 2011., 8CD005191
• [29]Room R, Babor T, Rehm J: Alcohol and public health: a review. Lancet 2005, 365:519-530.
• [30]Grant BF, Dawson DA: Introduction to the National Epidemiologic Survey on alcohol and related conditions. Alcohol Res Health 2006, 29:74-78.
• [31]Leon DA, McCambridge J: Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet 2006, 367(9504):52-56.
• [32]Plant M, Plant M: Binge Britain. Alcohol and the National Response. Oxford, U.K.: Oxford University Press; 2006.
• [33]Mohapatra S, Patra J, Popova S, Duhig A, Rehm J: Social cost of heavy drinking and alcohol dependence in high-income countries. Int J Public Health 2010, 55(3):149-157.
• [34]Science Group of the European Alcohol Health Forum: Alcohol, Work and Productivity. Brussels: EU Alcohol and Health Forum; 2011.
• [35]Anderson P, Baumberg B: Alcohol in Europe: a Public Health Perspective. A Report of the European Commission. London, UK: Institute of Alcohol Studies; 2006.
• [36]Paparrigopoulos T, Tzavellas E, Karaiskos D, Stefanis N, Mourikis I, Stahtea X, Liappas J: Family burden in alcohol dependence. Eur Psychiatry 2009, 24:449.
• [37]Rehm J, Rehm MX, Alho H, Allamani A, Aubin H-J, Bühringer G, Daeppen J-B, Frick U, Gual A, Heather N: Alcohol dependency treatment in the EU: a literature search and expert consultation about the availability and use of guidelines in all EU countries plus Iceland, Norway, and Switzerland. Int J Alcohol Drug Res 2013. epub ahead of print April 25
• [38]Babor T, Caetano R, Casswell S, Edwards G, Giesbrecht N, Graham K, Grube J, Gruenewald P, Hill L, Holder H, Homel R, Livingston M, Österberg E, Rehm J, Room R, Rossow I: Alcohol: No Ordinary Commodity. Research and Public Policy. 2nd Edition. Oxford and London: Oxford University Press; 2010.
• [39]Anderson P, Chisholm D, Fuhr D: Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol. Lancet 2009, 373(9682):2234-2246.
• [40]Bloom DE, Chisholm D, Jane-Llopis E, Prettner K, Stein A, Feigl A: From Burden to" Best Buys": Reducing the Economic Impact of Non-Communicable Disease in Low-and Middle-Income Countries. Geneva, Switzerland: World Economic Forum; 2011.
• [41]World Health Organization: Equity, Social Determinants and Public Health Programmes. Geneva, Switzerland: World Health Organization; 2010.
• [42]Rehm J, Anderson P, Gual A, Kraus L, Marmet S, Room R, Samokhvalov A, Scafato E, Shield K, Trapencieris M, Wiers R, Gmel G: The tangible common denominator of substance use disorders: a reply to commentaries to Rehm et al.(2013). Alcohol Alcohol 2014, 49(1):118-122.
• [43]Rehm J, Marmet S, Anderson P, Gual A, Kraus L, Nutt DJ, Room R, Samokhvalov AV, Scafato E, Trapencieris M, Wiers RW, Gmel G: Defining substance use disorders: do we really need more than heavy use? Alcohol Alcohol 2013, 48(6):633-640.
• [44]De Lorenze GN, Weisner C, Tsai AL, Satre DD, Quesenberry CP Jr: Excess mortality among HIV-infected patients diagnosed with substance use dependence or abuse receiving care in a fully integrated medical care program. Alcohol Clin Exp Res 2011, 35(2):203-210.
• [45]O’Brien JM Jr, Lu B, Ali NA, Martin GS, Aberegg SK, Marsh CB, Lemeshow S, Douglas IS: Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult intensive care unit patients. Crit Care Med 2007, 35(2):345-350.
• [46]Cuijpers P, Riper H, Lemmers L: The effects on mortality of brief interventions for problem drinking: a meta-analysis. Addiction 2004, 99(7):839-845.
• [47]Carroll KM, Rounsaville BJ: A vision of the next generation of behavioral therapies research in the addictions. Addiction 2007, 102(6):850-862.
• [48]Hollon SD: The efficacy and effectiveness of psychotherapy relative to medications. Am Psychol 1996, 51(10):1025-1030.
• [49]Nathan PE, Scott SP, Dolan SL: Research on psychotherapy efficacy and effectiveness: between Scylla and Charybdis? Psychol Bull 2000, 126(6):964-981.
• [50]Kaner E, Bland M, Cassidy P, COulton S, Dale V, Deluca P, Gilvarry E, Godfrey C, Heather N, Myles J, Newbury-Birch D, Oyefeso A, Parrott S, Perryman K, Phillips T, Shenker D, Shepherd J, Drummond C: Pragmatic cluster randomised controlled trial of the effectiveness and cost-effectiveness of screening and brief alcohol intervention in primary care in England. BMJ 2012, 346:e8501.